|
1
|
Roelants C, Pillet C, Franquet Q, Sarrazin C, Peilleron N, Giacosa S, Guyon L, Fontanell A, Fiard G, Long JA, Descotes JL, Cochet C, Filhol O. Ex-Vivo Treatment of Tumor Tissue Slices as a Predictive Preclinical Method to Evaluate Targeted Therapies for Patients with Renal Carcinoma. Cancers (Basel) 2020; 12:cancers12010232. [PMID: 31963500 PMCID: PMC7016787 DOI: 10.3390/cancers12010232] [Citation(s) in RCA: 33] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2019] [Revised: 01/08/2020] [Accepted: 01/15/2020] [Indexed: 12/14/2022] Open
Abstract
Clear cell renal cell carcinoma (ccRCC) is the third type of urologic cancer. At time of diagnosis, 30% of cases are metastatic with no effect of chemotherapy or radiotherapy. Current targeted therapies lead to a high rate of relapse and resistance after a short-term response. Thus, a major hurdle in the development and use of new treatments for ccRCC is the lack of good pre-clinical models that can accurately predict the efficacy of new drugs and allow the stratification of patients into the correct treatment regime. Here, we describe different 3D cultures models of ccRCC, emphasizing the feasibility and the advantage of ex-vivo treatment of fresh, surgically resected human tumor slice cultures of ccRCC as a robust preclinical model for identifying patient response to specific therapeutics. Moreover, this model based on precision-cut tissue slices enables histopathology measurements as tumor architecture is retained, including the spatial relationship between the tumor and tumor-infiltrating lymphocytes and the stromal components. Our data suggest that acute treatment of tumor tissue slices could represent a benchmark of further exploration as a companion diagnostic tool in ccRCC treatment and a model to develop new therapeutic drugs.
Collapse
Affiliation(s)
- Caroline Roelants
- Université Grenoble Alpes, Inserm, CEA, IRIG-Biology of Cancer and Infection, UMR_S 1036, F-38000 Grenoble, France; (C.R.); (Q.F.); (C.S.); (N.P.); (S.G.); (L.G.); (C.C.)
- Inovarion, 75005 Paris, France
| | - Catherine Pillet
- Université Grenoble Alpes, Inserm, CEA, IRIG-Biologie à Grande Echelle, UMR 1038, F-38000 Grenoble, France;
| | - Quentin Franquet
- Université Grenoble Alpes, Inserm, CEA, IRIG-Biology of Cancer and Infection, UMR_S 1036, F-38000 Grenoble, France; (C.R.); (Q.F.); (C.S.); (N.P.); (S.G.); (L.G.); (C.C.)
- Centre hospitalier universitaire Grenoble Alpes, CS 10217, 38043 Grenoble CEDEX 9, France; (A.F.); (G.F.); (J.-A.L.); (J.-L.D.)
| | - Clément Sarrazin
- Université Grenoble Alpes, Inserm, CEA, IRIG-Biology of Cancer and Infection, UMR_S 1036, F-38000 Grenoble, France; (C.R.); (Q.F.); (C.S.); (N.P.); (S.G.); (L.G.); (C.C.)
- Centre hospitalier universitaire Grenoble Alpes, CS 10217, 38043 Grenoble CEDEX 9, France; (A.F.); (G.F.); (J.-A.L.); (J.-L.D.)
| | - Nicolas Peilleron
- Université Grenoble Alpes, Inserm, CEA, IRIG-Biology of Cancer and Infection, UMR_S 1036, F-38000 Grenoble, France; (C.R.); (Q.F.); (C.S.); (N.P.); (S.G.); (L.G.); (C.C.)
- Centre hospitalier universitaire Grenoble Alpes, CS 10217, 38043 Grenoble CEDEX 9, France; (A.F.); (G.F.); (J.-A.L.); (J.-L.D.)
| | - Sofia Giacosa
- Université Grenoble Alpes, Inserm, CEA, IRIG-Biology of Cancer and Infection, UMR_S 1036, F-38000 Grenoble, France; (C.R.); (Q.F.); (C.S.); (N.P.); (S.G.); (L.G.); (C.C.)
| | - Laurent Guyon
- Université Grenoble Alpes, Inserm, CEA, IRIG-Biology of Cancer and Infection, UMR_S 1036, F-38000 Grenoble, France; (C.R.); (Q.F.); (C.S.); (N.P.); (S.G.); (L.G.); (C.C.)
| | - Amina Fontanell
- Centre hospitalier universitaire Grenoble Alpes, CS 10217, 38043 Grenoble CEDEX 9, France; (A.F.); (G.F.); (J.-A.L.); (J.-L.D.)
| | - Gaëlle Fiard
- Centre hospitalier universitaire Grenoble Alpes, CS 10217, 38043 Grenoble CEDEX 9, France; (A.F.); (G.F.); (J.-A.L.); (J.-L.D.)
| | - Jean-Alexandre Long
- Centre hospitalier universitaire Grenoble Alpes, CS 10217, 38043 Grenoble CEDEX 9, France; (A.F.); (G.F.); (J.-A.L.); (J.-L.D.)
| | - Jean-Luc Descotes
- Centre hospitalier universitaire Grenoble Alpes, CS 10217, 38043 Grenoble CEDEX 9, France; (A.F.); (G.F.); (J.-A.L.); (J.-L.D.)
| | - Claude Cochet
- Université Grenoble Alpes, Inserm, CEA, IRIG-Biology of Cancer and Infection, UMR_S 1036, F-38000 Grenoble, France; (C.R.); (Q.F.); (C.S.); (N.P.); (S.G.); (L.G.); (C.C.)
| | - Odile Filhol
- Université Grenoble Alpes, Inserm, CEA, IRIG-Biology of Cancer and Infection, UMR_S 1036, F-38000 Grenoble, France; (C.R.); (Q.F.); (C.S.); (N.P.); (S.G.); (L.G.); (C.C.)
- Correspondence: ; Tel.: +33-(0)4-38785645; Fax: +33-(0)4-38785058
| |
Collapse
|